tiprankstipranks
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksStock ScreenerCompare StocksPenny Stock ScreenerTop Product Insights Stocks
Daily Updates
Daily Analyst RatingsTrending StocksTop Stock GainersTop Stock LosersMost Active StocksDividend StocksChatGPT Stocks
New
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarMarket Holidays
ETF Research Tools
ETF CenterETF ScreenerTop ETFs by Smart Score
New
Compare ETFsTop ETFs by AUM
ETFs On the Move
Top ETF GainersTop ETF LosersMost Active ETFs
ETF Ideas
S&P 500 Index ETFsNasdaq 100 Index ETFsS&P 500 Sector ETFsBond ETFsCommodity ETFsCurrency ETFsIndustry ETFs
Best Dividend StocksBest High Yield Dividend StocksDividend Aristocrats
New
Dividend Stock ComparisonDividend Calculator
Popular
Dividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
My PortfolioMy WatchlistMy PerformanceMy Portfolio AnalysisCrowd Insights
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
Education
TipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityCareersContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Options Profit Calculator
New
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
ETF Research Tools
ETF Center
ETF Screener
New
Top ETFs by Smart Score
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Aristocrats
New
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Crypto Center
Bitcoin
Ethereum
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
Plans & Pricing

OCUP Stock Latest News

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Press ReleasesOcuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16d ago
OCUP
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
Press ReleasesOcuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
26d ago
OCUP
Ocuphire Pharma provides anticipated 2023 milestones
The FlyOcuphire Pharma provides anticipated 2023 milestones
2M ago
OCUP
Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer
Press ReleasesOcuphire Appoints Rick Rodgers as Interim Chief Executive Officer
2M ago
OCUP
Ocuphire Pharma appoints Rick Rodgers as interim CEO
The FlyOcuphire Pharma appoints Rick Rodgers as interim CEO
2M ago
OCUP
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
Press ReleasesOcuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
2M ago
OCUP
Ocuphire Pharma reports FY22 EPS $1.58, consensus 6c
The FlyOcuphire Pharma reports FY22 EPS $1.58, consensus 6c
2M ago
OCUP
Ocuphire Pharma announces APX3330 Phase 2 data presentations at retina meetings
The FlyOcuphire Pharma announces APX3330 Phase 2 data presentations at retina meetings
4M ago
OCUP
Ocuphire Pharma announces FDA acceptance of NDA for Nyxol
The FlyOcuphire Pharma announces FDA acceptance of NDA for Nyxol
4M ago
OCUP
OCUP Tanks as Clinical Data Disappoints
Market NewsOCUP Tanks as Clinical Data Disappoints
4M ago
OCUP
Ocuphire Pharma price target lowered to $20 from $26 at H.C. Wainwright
The FlyOcuphire Pharma price target lowered to $20 from $26 at H.C. Wainwright
4M ago
OCUP
Ocuphire craters 31% after trial evaluating oral APX3330 fails to meet endpoint
The FlyOcuphire craters 31% after trial evaluating oral APX3330 fails to meet endpoint
5M ago
OCUP
Ocuphire Pharma did not meet the primary endpoint in Oral APX3330 trial
The FlyOcuphire Pharma did not meet the primary endpoint in Oral APX3330 trial
5M ago
OCUP
Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
Press ReleasesOcuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
5M ago
OCUP
Ocuphire Pharma enrolls first patient in VEGA-2 Phase 3 trial of Nyxol
The FlyOcuphire Pharma enrolls first patient in VEGA-2 Phase 3 trial of Nyxol
5M ago
OCUP
Analysts See Extravagant Gains for These 2 ‘Strong Buy’ Penny Stocks
Stock Analysis & IdeasAnalysts See Extravagant Gains for These 2 ‘Strong Buy’ Penny Stocks
5M ago
OCUP
RIGL
Ocuphire Pharma submits NDA to FDA for Nyxol
The FlyOcuphire Pharma submits NDA to FDA for Nyxol
6M ago
OCUP
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
Press ReleasesOcuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
6M ago
OCUP
Ocuphire to Present at Five Upcoming Investor/Industry Conferences
Press ReleasesOcuphire to Present at Five Upcoming Investor/Industry Conferences
7M ago
OCUP
Ocuphire Pharma enters exclusive license agreement with FamyGen Life Sciences
The FlyOcuphire Pharma enters exclusive license agreement with FamyGen Life Sciences
7M ago
OCUP
VTRS
Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)
Press ReleasesOcuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)
7M ago
OCUP
Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting
Press ReleasesOcuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting
8M ago
OCUP